Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Apple Turns 50: From Garage Startup to AI Crossroads 
TEL AVIV, Israel and AHMEDABAD, India, July 05, 2017 -- (NASDAQ:PAHC)
Phibro Animal Health Corporation and Zydus Cadila today announced their intention to enter into a long-term arrangement to license Phibro’s innovative poultry vaccine technologies and know-how to a new vaccine manufacturing facility to be built by Zydus Cadila to serve the fast growing poultry market in India.
Jack Bendheim, Chairman, President and Chief Executive Officer of Phibro, remarked, “We are proud of the more than 20-year partnership with Zydus Cadila serving the Indian animal health market and we view this as an exciting next step in our relationship.”
Speaking on the development Mr. Pankaj R. Patel, Chairman and Managing Director, Zydus group said, “Our endeavor has always been to enable access to innovative therapies across geographies and this agreement with Phibro will help bring innovations to the poultry market in India. The availability of new advanced poultry vaccines, which were until now being imported into India, adds a new dimension to the Make-in-India movement in the animal health segment.”
About Zydus Animal Health
With a strong presence in the livestock and poultry segments, Zydus Animal Health is India’s leading animal healthcare player and a market leader in various therapeutic segments which include antibacterials, NSAIDs, antimastitis, tonics and poultry vaccines amongst others in India. Zydus Animal Health has introduced the highest number of ‘First in India’ products, in keeping with its mission to provide innovative solutions that improve animal health and farm productivity.
About Zydus Cadila
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 20000 people worldwide and is dedicated to creating healthier communities globally. The group aspires to be a research-based pharmaceutical company by 2020.
About Phibro Animal Health Corporation
Phibro Animal Health Corporation is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for use in the production of poultry, swine, dairy, beef cattle and aquaculture. For further information, please visit www.pahc.com.
Contact: Phibro Animal Health Corporation Richard Johnson Chief Financial Officer +1-201-329-7300 or [email protected] Sujatha Rajesh Vice President – Corporate Communications Zydus Cadila +91-997-405-1180 [email protected]
